articleJournal of Clinical OncologyMay 17, 2011BRONZE OA

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

MSMax S. ToppPKPeter KuferNGNicola GökbugetMGMariele GoebelerMKMatthias Klinger

Goethe University Frankfurt · Wockhardt (United States) · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Results

Twenty-one patients were treated, of whom 16 patients became MRD negative. One patient was not evaluable due to a grade 3 adverse event leading to treatment discontinuation. Among the 16 responders, 12 patients had been molecularly refractory to previous chemotherapy. Probability for relapse-free survival is 78% at a median follow-up of 405 days. The most frequent grade 3 and 4 adverse event was lymphopenia, which was completely reversible like most other adverse events.

Conclusion

Blinatumomab is an efficacious and well-tolerated treatment in patients with MRD-positive B-lineage ALL after intensive chemotherapy. T cells engaged by blinatumomab seem capable of eradicating chemotherapy-resistant tumor cells that otherwise cause clinical relapse.

Citation impact

911
total citations
FWCI
88.09
Percentile
100%
References
25
Citations per year

Authors

29

Topics & keywords

Topics
Keywords
  • Blinatumomab
  • Medicine
  • Minimal residual disease
  • Oncology
  • Internal medicine
  • Acute lymphocytic leukemia
  • Chemotherapy
  • Immunology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.